

4SC

FY17 results

Yakult joined the pivotal RESMAIN study

Together with its Q417 results announced last week, 4SC also reported progress with its R&D activities. All three lead assets – resminostat, 4SC-202 and 4SC-208 – remain on course to be developed for specialty dermato-oncological indications. New details include an update on the 4SC-202 development plan and the news that 4SC's Japanese partner, Yakult Honsha, joined 4SC's pivotal resminostat study and will enrol patients in Japan. Our valuation is largely unchanged at €349m or €11.4/share (€11.3/share previously).

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/16	2.1	(10.9)	(0.54)	0.0	N/A	N/A
12/17	4.2	(10.0)	(0.41)	0.0	N/A	N/A
12/18e	4.7	(17.6)	(0.57)	0.0	N/A	N/A
12/19e	3.1	(19.2)	(0.63)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Resminostat on track for pivotal data readout in H119

A recent major development was the news from 4SC's partner Yakult that it had joined the pivotal RESMAIN study. By enrolling additional patients in Japan, Yakult will be able to submit resminostat for approval, assuming the data are positive. In our view, this indicates an external validation of 4SC's R&D strategy. Resminostat (a broad-spectrum histone deacetylase [HDAC] inhibitor) is uniquely positioned as a maintenance therapy to make remissions more durable for patients with advanced cutaneous T-cell lymphoma (CTCL) who have achieved remission with systemic therapy. Timelines remain unchanged for the study to report data in H119. Yakult is also committed to initiate the next Phase II trial with resminostat in biliary tract cancer patients in Japan after it reported [positive data](#) from a Phase I trial.

Broad development plan for 4SC-202

4SC has a broad development plan for its second lead product 4SC-202 (HDAC Class I specific inhibitor) positioned to be used in combination with checkpoint inhibitors with the rationale to tackle the high non-responder issue. 4SC is running a Phase Ib/II trial SENSITIZE in unresectable melanoma in combination with Keytruda. Final results are expected in H119, but the company plans several interim readouts starting this year. Another investigator-led Phase II study will test 4SC-202 in combination with the anti-PD-L1 antibody avelumab for treating GI tumours. Beyond SENSITIZE and EMERGE, the company sees potential for 4SC-202 in other solid tumours and plans to explore this in several other Phase II trials in combination with checkpoint inhibitors. 4SC will use the insights from these trials for potential partnering discussions, while ultimately the company plans to run its own pivotal trial with 4SC-202 in an orphan indication Merkel-cell carcinoma.

Valuation: Marginally upped to €349m or €11.4/share

We have updated our rNPV-based valuation which is now €349m or €11.4/share versus €345m or €11.3/share previously, due to rolling our model forward. We keep all our assumptions for the assets unchanged. First interim data from both SENSITIZE and EMERGE studies are expected later this year.

Pharma & biotech

28 March 2018

Price €7.47

Market cap €229m

Net cash (€m) at 31 December 2017 41.3

Shares in issue 30.7m


Free float 30%

Code VSC

Primary exchange Frankfurt (Xetra)

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs 3.0 54.2 187.6

Rel (local) 7.4 68.4 188.2

52-week high/low €8.5 €2.3

Business description

4SC is a Munich-based cancer biopharmaceutical company. Resminostat (HDAC inhibitor) is the lead candidate for cutaneous T-Cell lymphoma (CTCL, pivotal study started in Q416). It has a second compound, 4SC-202 (Phase Ib/II started in Q317) and a preclinical asset, 4SC-208. 4SC also has several partners including Yakult Honsha for resminostat in Japan in various indications.

Next events

Initiation Phase II trial with resminostat in biliary tract cancer by Yakult H118

Initiation of EMERGE study H118

Top-line data from SENSITIZE study H218

Safety data from EMERGE study H218

Analysts

Jonas Peculis +44 (0)20 3077 5728

Alice Nettleton +44 (0)20 3077 5700

healthcare@edisongroup.com
[Edison profile page](#)

**4SC is a research client of
Edison Investment Research
Limited**

Financials and valuation

Total FY17 revenues of €4.2m were ahead of our estimate of €3.4m and included income from services, changes in deferred income accounting and smaller milestone payments, including “a single digit million euros” milestone from Immunic as announced in December 2017. Total operating expenses of €14.6m were better than our expected €17.0m mainly due to lower R&D spend of €11.5m (our estimate €14.0m). 4SC guided a monthly cash burn of €1.2-1.4m for 2017, but due to the deferral of clinical expenses from 2017 into 2018, this measure was better than expected at €723k.

Following the postponed clinical costs we have revised our estimates and now forecast FY18 R&D spend of €19.6m compared with €16.8m previously, while our FY18 G&A estimate is little changed at €3.2m. The cash position at the year-end was €41.3m. After fine-tuning the estimates, our model is in line with 4SC's updated guidance of monthly cash burn of €1.8-2.0m for FY18.

4SC received a milestone payment from Yakult after it had joined the RESMAIN study. While the specific amount has not been disclosed, we include €2m in our financial estimates in H118. The existing cash should be sufficient to fund operations until FY20.

Our updated rNPV-based valuation is marginally higher at €349m or €11.4/share compared to €345m or €11.3/share previously. All our assumptions for the risk-adjusted NPV valuation of the assets are unchanged, as summarised in our last [outlook report](#).

Exhibit 1: Risked NPV valuation

Product	Indication	Partner	Launch	Peak sales, (€m)	NPV (€m)	Probability of success	rNPV (€m)	rNPV/ share (€)
Core assets/indications								
Resminostat	Maintenance CTCL		2021	216	548.5	50%	274.2	8.9
4SC-202	r/r MCC		2022	237	222.4	20%	44.5	1.5
4SC-208	Advanced BCC		2023	386	386.2	5%	19.3	0.6
Out-licensed assets/indications								
Resminostat	Biliary tract cancer	Yakult Honsha	2024	149	36.2	20%	15.9	0.5
4SC-205		Link Health			32.4	3%	11.3	0.4
Kv1.3 inhibitors		Maruho			58.4	3%	10.5	0.3
R&D expenses					(54.0)		(54.0)	(1.8)
Admin expenses					(10.0)		(10.0)	(0.3)
Net cash (as of 20 March 2018)					37.0		37.0	1.2
Total					1,257.2		348.7	11.4

Source: Edison Investment Research

Upcoming newsflow, within cash reach

2018

- First data read-out from Phase Ib/II SENSITIZE study in melanoma (**4SC-202** with pembrolizumab) in H218 (first patient in Q417)
- Completion of recruitment to **resminostat** pivotal RESMAIN CTCL study
- Initiation of the next Phase II trial with **resminostat** in biliary tract cancer by Yakult in H118
- Initiation of Phase II EMERGE study (**4SC-202** with avelumab) in H118, and safety data expected H218
- Data from preclinical studies with **4SC-202** in combination with checkpoint inhibitors published at oncological conferences in 2018



- Expected initiation of additional **4SC-202** checkpoint combination studies, including the first triple combination therapy study in collaboration with a new partner
- At least one new non-core asset licensing/partnering deal

2019

- CTCL pivotal RESMAIN study with **resminostat** data read-out in H119
- Final data read-out from Phase Ib/II SENSITIZE study
- Interim data from Phase II EMERGE study

2020

- **4SC-208** entering the clinic in Q119, data read-out in Q419/Q120

2021

- Pivotal study with **4SC-202** following on from melanoma and GI cancer studies in MCC in Q119, data readout 2021

Exhibit 2: Financial summary

	€'000s	2015	2016	2017	2018e	2019e
Year end 31 December		IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS						
Revenue		3,266	2,060	4,197	4,724	3,133
Cost of sales		(1,763)	(76)	(574)	(574)	(574)
Gross profit		1,503	1,984	3,623	4,150	2,559
R&D expenditure		(7,255)	(10,601)	(11,475)	(19,555)	(19,461)
Administrative, distribution and other		(3,163)	(3,175)	(3,084)	(3,195)	(3,289)
Operating profit		(8,915)	(11,792)	(10,936)	(18,600)	(20,191)
Intangible amortisation		(827)	(892)	(892)	(892)	(892)
Exceptionals (impairment / restructuring costs)			0	0	0	0
Share-based payments		2	0	0	(20)	(20)
EBITDA		(7,914)	(10,900)	(9,819)	(17,463)	(19,054)
Operating profit (before amort and except.)			(8,090)	(10,900)	(10,044)	(17,688)
Net interest		(331)	(14)	9	100	100
Other (profit/loss from associates)		58	711	0	0	0
Profit before tax (norm)		(8,421)	(10,914)	(10,035)	(17,588)	(19,179)
Profit before tax (FRS 3)		(9,188)	(11,095)	(10,927)	(18,500)	(20,091)
Tax		(40)	(71)	(33)	0	0
Profit after tax (norm)		(8,403)	(10,274)	(10,068)	(17,588)	(19,179)
Profit after tax (FRS 3)		(9,228)	(11,166)	(10,960)	(18,500)	(20,091)
Average number of shares outstanding (m)			14.3	19.0	24.8	30.6
EPS - normalised (€)		(0.59)	(0.54)	(0.41)	(0.57)	(0.63)
EPS - FRS 3 (€)		(0.64)	(0.59)	(0.44)	(0.60)	(0.66)
Dividend per share (€)		0.0	0.0	0.0	0.0	0.0
BALANCE SHEET						
Fixed assets		11,077	7,096	6,365	5,452	4,539
Intangible assets		9,123	6,499	5,694	4,806	3,918
Tangible assets		357	497	570	545	520
Investments and other		1,597	100	101	101	101
Current assets		22,415	11,959	41,548	22,957	4,522
Stocks		20	0	0	0	0
Debtors		94	95	30	30	30
Cash		21,476	10,048	41,327	22,736	4,301
Other current assets		817	1,816	191	191	191
Current liabilities		(5,593)	(3,257)	(2,759)	(3,636)	(2,840)
Creditors		(688)	(834)	(1,175)	(1,175)	(1,175)
Short-term borrowings		(1,962)	0	0	0	0
Deferred revenue (short term)		(1,779)	(1,431)	(1,485)	(2,362)	(1,566)
Other current liabilities		(1,164)	(992)	(99)	(99)	(99)
Long-term liabilities		(1,471)	(525)	(461)	(511)	(486)
Long-term borrowings		0	0	0	0	0
Deferred revenue (long term)		(1,433)	(493)	(394)	(444)	(419)
Other long-term liabilities		(38)	(32)	(67)	(67)	(67)
Net assets		26,428	15,273	44,693	24,263	5,735
CASH FLOW						
Operating cash flow		(8,916)	(12,320)	(8,508)	(18,390)	(18,234)
Net interest		(2)	(531)	0	3	3
Tax		(40)	(71)	(33)	0	0
Capex		(109)	(404)	(168)	(200)	(200)
Expenditure on intangibles		(114)	(60)	(4)	(4)	(4)
Acquisitions/disposals		0	2,808	39	0	0
Financing		27,608	0	39,953	0	0
Other		4,333	650	0	0	0
Net cash flow		22,760	(9,928)	31,279	(18,591)	(18,435)
Opening net debt/(cash)		3,246	(19,514)	(10,048)	(41,327)	(22,736)
HP finance leases initiated		0	0	0	0	0
Other		0	462	0	0	0
Closing net debt/(cash)		(19,514)	(10,048)	(41,327)	(22,736)	(4,301)

Source: Company accounts, Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by 4SC and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2018. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.